CStone Pharmaceuticals’ Sugemalimab Files for New Indication with NMPA for Esophageal Cancer
China-based CStone Pharmaceuticals (HKG: 2616) has announced that the National Medical Products Administration (NMPA) has...
HKG: 2616
CStone Pharmaceuticals’ Sugemalimab Study Published in JCO for R/R ENKTL Treatment
CStone Pharmaceuticals (HKG: 2616), a China-based biopharmaceutical company, announced that the Journal of Clinical Oncology...
CStone Pharmaceuticals Reports 97.54% Revenue Growth in 2022, Driven by Drug Sales and Licensing Fees
China-based CStone Pharmaceuticals (HKG: 2616) released its 2022 financial report, recording total revenues of RMB...
CStone’s Ayvakit Shows Significant Improvements in ISM at AAAAI Meeting
China-based CStone Pharmaceuticals (HKG: 2616) announced that its US partner, Blueprint Medicines, published detailed data...
CStone’s PD-L1 Inhibitor Sugemalimab Accepted for Review in Gastric Cancer
China-based CStone Pharmaceuticals (HKG: 2616) has announced that the National Medical Products Administration (NMPA) has...
CStone’s Sugemalimab Accepted for EU Marketing Authorization by EMA
China-based CStone Pharmaceuticals (HKG: 2616) has announced that the European Medicine Agency (EMA) has accepted...
Roche Returns Global Rights to Blueprint’s RET Inhibitor Gavreto
US-based biotech Blueprint Medicines has announced that Swiss giant Roche (SWX: ROG, OTCMKTS: RHHBY) has...
CStone’s RET Inhibitor Gavreto Approved in Taiwan for Lung and Thyroid Cancers
CStone Pharmaceuticals (HKG: 2616) has announced receiving marketing approval in Taiwan for its RET inhibitor...
Hengrui Pharmaceuticals Appoints Dr. Jiang Ningjun as Deputy General Manager and CSO
China-based Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced the appointment of Dr. “Frank” Jiang Ningjun...
CStone Pharmaceuticals Achieves Primary Endpoint in GEMSTONE-304 Study for Sugemalimab
China-based CStone Pharmaceuticals (HKG: 2616) has announced the achievement of the primary endpoint in the...
CStone Pharmaceuticals Publishes Ayvakit Study Results on Oncologist Website
China-based CStone Pharmaceuticals (HKG: 2616) has published the results of the China-based bridging NAVIGATOR study...
CStone’s Sugemalimab MAA Accepted by UK MHRA for NSCLC Treatment
China-based CStone Pharmaceuticals (HKG: 2616) has announced that the Medicines and Healthcare products Regulatory Agency...
CStone Pharmaceuticals Launches AML Public Welfare Project with China Social Welfare Foundation
The acute myeloid leukemia (AML) public welfare project, initiated by the China Social Welfare Foundation...
CStone Pharmaceuticals Suspends Suzhou Plant Operations to Cut Costs
CStone Pharmaceuticals (HKG: 2616) has officially responded to recent news reports regarding the suspension of...
CStone Launches Patient Assistance Program for IDH1 Inhibitor Tibsovo
CStone Pharmaceuticals (HKG: 2616) has announced the launch of a patient assistance scheme to support...
CStone Pharmaceuticals Suspends Operations at Suzhou Plant to Cut Costs
CStone Pharmaceuticals (HKG: 2616) has decided to suspend manufacturing operations at its Suzhou industrialization plant,...
CStone’s PD-L1 Inhibitor Sugemalimab Achieves Primary Endpoint in Gastric Cancer Study
China-based CStone Pharmaceuticals (HKG: 2616) has announced that its GEMSTONE-303 study for the programmed death-ligand...
CStone Pharmaceuticals Partners with Rigen Biotech on Thyroid Cancer RET Gene Testing
China-based CStone Pharmaceuticals (HKG: 2616) has entered into a partnership with Shanghai Rigen Biotech to...
InnoCare Pharma and CStone Pharmaceuticals’ Drugs Receive Prioritized CDE Review
The Center for Drug Evaluation (CDE) has granted prioritized review status to InnoCare Pharma’s (HKG:...
CStone Pharmaceuticals’ H1 2022 Revenue Jumps 229% on Drug Sales Growth
China-based CStone Pharmaceuticals (HKG: 2616) reported RMB 262 million (USD 49.4 million) in revenue for...